ALTEOGEN Inc. (196170.KQ)
KRW 286500.0
(-3.54%)
KRW 286500.0
(-3.54%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 40.93 Billion KRW | 137.12% |
| 2022 | 38.78 Billion KRW | 30.14% |
| 2021 | 29.8 Billion KRW | 9.96% |
| 2020 | 27.1 Billion KRW | 107.16% |
| 2019 | 13.08 Billion KRW | 37.69% |
| 2018 | 9.5 Billion KRW | 33.48% |
| 2017 | 7.11 Billion KRW | 19.07% |
| 2016 | 5.97 Billion KRW | 36.22% |
| 2015 | 4.38 Billion KRW | 34.93% |
| 2014 | 3.25 Billion KRW | 47.97% |
| 2013 | 2.19 Billion KRW | 11.64% |
| 2012 | 1.96 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 16.44 Billion KRW | 12.04% |
| 2024 Q1 | 14.67 Billion KRW | 59.5% |
| 2023 FY | 91.96 Billion KRW | 137.12% |
| 2023 Q3 | 14.63 Billion KRW | 240.76% |
| 2023 Q4 | 9.2 Billion KRW | -37.14% |
| 2023 Q2 | 4.29 Billion KRW | -64.3% |
| 2023 Q1 | 12.03 Billion KRW | 26.47% |
| 2022 FY | 38.78 Billion KRW | 30.14% |
| 2022 Q4 | 9.51 Billion KRW | -18.92% |
| 2022 Q3 | 11.73 Billion KRW | 30.4% |
| 2022 Q2 | 8.99 Billion KRW | 21.35% |
| 2022 Q1 | 7.41 Billion KRW | 81.64% |
| 2021 Q3 | 4.47 Billion KRW | -65.85% |
| 2021 Q4 | 4.08 Billion KRW | -8.84% |
| 2021 Q1 | 8.48 Billion KRW | -63.54% |
| 2021 FY | 29.8 Billion KRW | 9.96% |
| 2021 Q2 | 13.11 Billion KRW | 54.55% |
| 2020 Q2 | 5.58 Billion KRW | 102.3% |
| 2020 Q4 | 23.27 Billion KRW | 378.53% |
| 2020 Q3 | 4.86 Billion KRW | -12.88% |
| 2020 FY | 27.1 Billion KRW | 107.16% |
| 2020 Q1 | 2.75 Billion KRW | -27.86% |
| 2019 Q3 | 2.51 Billion KRW | -22.96% |
| 2019 Q1 | 3.81 Billion KRW | 585.06% |
| 2019 FY | 13.08 Billion KRW | 37.69% |
| 2019 Q4 | 3.82 Billion KRW | 51.93% |
| 2019 Q2 | 3.26 Billion KRW | -14.38% |
| 2018 FY | 9.5 Billion KRW | 33.48% |
| 2018 Q4 | 557.08 Million KRW | -82.28% |
| 2018 Q3 | 3.14 Billion KRW | 33.5% |
| 2018 Q2 | 2.35 Billion KRW | -10.49% |
| 2018 Q1 | 2.63 Billion KRW | -42.25% |
| 2017 Q2 | 1.53 Billion KRW | 4.63% |
| 2017 FY | 7.11 Billion KRW | 19.07% |
| 2017 Q4 | 4.55 Billion KRW | 240.87% |
| 2017 Q1 | 1.46 Billion KRW | -16.91% |
| 2017 Q3 | 1.33 Billion KRW | -12.98% |
| 2016 Q2 | 1.39 Billion KRW | 43.22% |
| 2016 Q4 | 1.76 Billion KRW | 16.54% |
| 2016 FY | 5.97 Billion KRW | 36.22% |
| 2016 Q1 | 972.86 Million KRW | 7.1% |
| 2016 Q3 | 1.51 Billion KRW | 8.77% |
| 2015 Q2 | 705.33 Million KRW | -35.15% |
| 2015 Q1 | 1.08 Billion KRW | 28.55% |
| 2015 FY | 4.38 Billion KRW | 34.93% |
| 2015 Q4 | 908.33 Million KRW | 160.62% |
| 2015 Q3 | 348.53 Million KRW | -50.59% |
| 2014 Q4 | 846.09 Million KRW | 30.87% |
| 2014 FY | 3.25 Billion KRW | 47.97% |
| 2014 Q1 | 731.22 Million KRW | 25.54% |
| 2014 Q2 | 1.02 Billion KRW | 40.68% |
| 2014 Q3 | 646.5 Million KRW | -37.15% |
| 2013 FY | 2.19 Billion KRW | 11.64% |
| 2013 Q1 | 516.58 Million KRW | 0.0% |
| 2013 Q2 | 516.58 Million KRW | 0.0% |
| 2013 Q4 | 582.44 Million KRW | 0.0% |
| 2013 Q3 | 582.44 Million KRW | 12.75% |
| 2012 FY | 1.96 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 62.782% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -421.747% |
| BINEX Co., Ltd. | 55.67 Billion KRW | 26.475% |
| Bioneer Corporation | 204.55 Billion KRW | 79.989% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -428.868% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 37.326% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | -26.461% |
| Helixmith Co., Ltd | 37.36 Billion KRW | -9.549% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 85.684% |
| Medy-Tox Inc. | 110.88 Billion KRW | 63.083% |
| Peptron, Inc. | 16.65 Billion KRW | -145.761% |
| Amicogen, Inc. | 52.82 Billion KRW | 22.505% |
| Genexine, Inc. | 41.62 Billion KRW | 1.665% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -153.211% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 58.492% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 54.232% |
| SillaJen, Inc. | 5.11 Billion KRW | -700.731% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | -59.503% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | -16.13% |
| Genomictree Inc. | 16.26 Billion KRW | -151.679% |
| MedPacto, Inc. | 26.91 Billion KRW | -52.066% |
| D&D Pharmatech | 32.16 Billion KRW | -27.274% |
| EASY BIO,Inc. | 29.67 Billion KRW | -37.96% |
| GI Innovation, Inc. | 57.59 Billion KRW | 28.923% |